Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, according to its chief corporate brand officer Lina Polimeni.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Lilly’s Omvoh is already recommended by NICE to treat certain cases of ulcerative colitis, another of the two main forms of ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.